Watch EVH. Know when insiders buy.
One email the day a filing lands. Free.
Work order
44
WATCH · insiders 36, shorts 51
Insiders, 90 days
−$329K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $488.4MP/E —DIV YIELD —FCF YIELD —REV TTM $2.1B −4.5%NET INCOME −$505MNET DEBT $169.5M52W 2.17 – 9.99NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $652.5M | +46.9% | 12.4% | −$9.6M | −$28.4M | — | -0.25 | −$9.3M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $496.2M | +2.6% | 16.9% | −$10.6M | −$26.6M | — | -0.24 | −$984K | — | — | May 7 |
| Q4 2025 · Dec 31 | $468.7M | −27.5% | 20.7% | −$408.2M | −$429.1M | — | -3.84 | $48.8M | — | — | Feb 25 |
| Q3 2025 · Sep 30 | $479.5M | −22.8% | 20.8% | $886K | −$20.9M | — | -0.24 | $15.8M | — | — | Feb 25 |
| Q2 2025 · Jun 30 | $444.3M | −31.3% | 22.6% | −$1.2M | −$19.9M | −1346.7% | -0.44 | −$30.3M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $483.6M | −24.4% | 21.2% | −$1.6M | −$64.6M | — | -0.63 | $4.6M | — | — | May 7 |
| Q4 2024 · Dec 31 | $646.5M | +16.3% | 11.7% | −$18.6M | −$22.8M | — | -0.27 | −$26.2M | — | — | Feb 25 |
| Q3 2024 · Sep 30 | $621.4M | +21.6% | 13.0% | −$16.3M | −$23.1M | — | -0.27 | $18.7M | — | — | Feb 25 |
| Q2 2024 · Jun 30 | $647.1M | — | 16.5% | $7.8M | $1.6M | — | -0.06 | $21.4M | — | — | Feb 25 |
| Q1 2024 · Mar 31 | $639.7M | — | 16.3% | −$13.4M | −$17.3M | — | -0.22 | $4.9M | — | — | Feb 25 |
| Q4 2023 · Dec 31 | $556.1M | — | 18.3% | −$21.4M | −$33.4M | — | -0.36 | $89.4M | — | — | Feb 25 |
| Q3 2023 · Sep 30 | $511M | — | 24.3% | −$17.9M | −$25.3M | — | -0.30 | $60.5M | — | — | Feb 21 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.9B | 21.3% | −$410.1M | −$534.5M | -28.5% | -5.07 | $38.8M | — | — | $40M | — |
| FY2024 · to Dec 31 | $2.6B | 14.4% | −$40.5M | −$61.6M | -2.4% | -0.81 | $18.8M | — | — | $0 | — |
| FY2023 · to Dec 31 | $2B | 23.4% | −$71.2M | −$113M | -5.8% | -1.28 | $142.6M | — | — | $0 | — |
| FY2022 · to Dec 31 | $1.4B | 23.4% | $3.6M | −$19.2M | -1.4% | -0.20 | −$11.6M | — | — | — | — |
| FY2021 · to Dec 31 | $908M | 27.6% | −$42.4M | −$37.6M | -4.1% | -0.44 | $38.7M | — | — | — | — |
| FY2020 · to Dec 31 | $924.6M | — | −$262.8M | −$334.2M | -36.1% | -3.94 | −$16.2M | — | — | — | — |
Every number comes from Evolent Health, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.